Skip to content

Dietary Treatment for IBS Within Primary Health Care

Dietary Treatment for IBS Within Primary Health Care

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05415488
Acronym
KIPIBS
Enrollment
240
Registered
2022-06-13
Start date
2022-08-15
Completion date
2025-09-15
Last updated
2023-12-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Brief summary

Irritable bowel syndrome (IBS) is a multifaceted disorder where diet plays a pivotal role in symptom generation and management. The traditional dietary advice given to patients in clinical settings are based on the NICE guidelines. Some of the advice included in these guidelines have limited scientific evidence. The aim of this study is to investigate the effectiveness of the traditional dietary advice in IBS, according to the NICE guidelines, within a primary health care setting, where treatment is delivered digitally and in groups of 8-12 individuals. As a sham comparator, one group will receive dietary advice according to the Swedish dietary guidelines regarding healthy eating habits.

Interventions

OTHEROnline dietary group treatment

Dietary advice will be given during one 90 minute online group session

Sponsors

Sahlgrenska University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Masking description

Participants will only be told that the both diets aim to relieve symptoms of IBS, and that none of the diets are expected to cure the disorder. No specific names of the diets will be given.

Intervention model description

Intervention study with 2 parallel arms (1:1)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosed with IBS (ROME IV) by physician * Age 18-50 * Ability to read and understand Swedish * Signed informed consent

Exclusion criteria

* Received dietary treatment for IBS previously * Manifestations of other conditions that may explain gastrointestinal symptoms

Design outcomes

Primary

MeasureTime frameDescription
Proportion of patients with significant symptom reductionFrom baseline vs. 6 weeks after group sessionA responder to treatment is defined as having a symptom reduction \>50 measured by IBS-SSS

Countries

Sweden

Contacts

Primary ContactSanna Nybacka, PhD
sanna.nybacka@gu.se+46736877771

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026